The RETRAIN Trial Phase 2

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

July 1, 2026

Conditions
Ischaemic Stroke
Interventions
DEVICE

Intermittent Pneumatic Compression

The IPC arm will use the Kendall SCD™ 700 Sequential Compression System, a routinely employed device for VTE prophylaxis in stroke patients. In this study, IPC sleeves will be applied bilaterally to the legs within 36 hours of stroke onset and operated according to the manufacturer's instructions. The intervention is distinguished by its cyclical external leg compression to enhance venous return, and it serves as the comparator to the geko® device for evaluating effects on cerebral blood flow and haemodynamics.

DEVICE

geko® T3

The geko® T3 device is a small, disposable, battery-powered neuromuscular electrostimulation device manufactured by Firstkind Ltd. In this study, the geko® will be applied bilaterally to the common peroneal nerve at the knee within 36 hours of stroke onset. It delivers transcutaneous electrical stimulation at 1 Hz, producing involuntary rhythmic foot dorsiflexion to activate the calf and foot muscle pumps. The intervention is distinguished from IPC by its mechanism of action (neuromuscular stimulation vs. external compression) and will be evaluated for its impact on cerebral haemodynamics, neurovascular coupling, and dynamic cerebral autoregulation during VTE prophylaxis.

Trial Locations (1)

CH2 1UL

RECRUITING

Countess of Chester Hospital, Chester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Innovate UK

OTHER_GOV

lead

Firstkind Ltd

INDUSTRY

NCT07197996 - The RETRAIN Trial Phase 2 | Biotech Hunter | Biotech Hunter